Ciclesonide | place in therapy review Jones A, Fay J, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;(1):CD003537. Juniper EF. How important is quality of life in pediatric asthma? Pediatr Pulmonol Suppl. 1997;15:17–21. Juniper EF, Guyatt G, Feeny D, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;5:35–46. Kanniess F, Richter K, Bohme S, Jorres RA, Magnussen H. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther. 2001;14:141–147. Kelly HW. Pharmaceutical characteristics that influence clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003;91:326–334. Langdon C, Adler M, Mehra S, Alexander M, Drollman A. Once-daily ciclesonide 80 or 320 mcg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med. 2005;99:1275–1285. Larj MJ, Bleecker ER. Therapeutic responses in asthma and COPD. Chest. 2004;126:138S–149S. Lee DK, Haggart K, Currie GP, Bates CE, Lipworth BJ. Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily vs fluticasone 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br J Clin Pharmacol. 2004;58:26–33. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic–pituitary–adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol. 2005;94:465–472. Magnussen H, Hellwig M, Hellbardt S, Josten J, Engelstätter R. Ciclesonide 80 mcg or 160 mcg once-daily and fluticasone propionate 88 mcg twice-daily similarly reduce asthma symptoms and rescue medication use in patients with mild-to-moderate asthma. Poster presented at: American Thoracic Society Annual Meeting; May 23, 2005; San Diego, CA. Poster G20. Masoli M, Fabian D, Holt S, Beasley R. Global burden of asthma. Available at: http://www.ginasthma.com/reportItem.asp?l1=2&l2=2&intId=94 (accessed July 28, 2005). Miller D, Ratner P, Condemi J, et al. Once-daily ciclesonide improves quality of life in pediatric patients with asthma. J Allergy Clin Immunol. 2005;115:S211. Nave R, Bethke TD, van Marle SP, Zech K. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet. 2004;43:479–486. Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol. 2005a;61:203–208. Nave R, Drollmann A, Steinijans VW, Zech K, Bethke TD. Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin. Int J Clin Pharmacol Ther. 2005b;43:264–270. Nave R, Gunawardena KA, Zech K, Bethke TD. Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar. Int J Clin Pharmacol Ther. 2006;44:1–7. Nayak A, Charous B, Finn A, et al. A novel inhaled corticosteroid ciclesonide significantly improves quality of life in patients with mild-to-moderate asthma. J Allergy Clin Immunol. 2005;115:S210. Neffen H, Ruff M, Zhang P, Lloyd M, Banerji D. Ciclesonide, administered once daily, has no effect on skeletal maturity in prepubertal children with mild, persistent asthma. J Allergy Clin Immunol. 2006;117(Suppl. 2):S184 (Abstract 714). Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med. 2006;100:375–384. Niphadkar P, Jagannath K, Joshi JM, et al. Comparison of the efficacy of ciclesonide 160 microg qd and budesonide 200 microg bid in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study. Clin Ther. 2005;27:1752–1763. O'Connell EJ. Optimizing inhaled corticosteroid therapy in children with chronic asthma. Pediatr Pulmonol. 2005;39:74–83. 248 O'Connor BJ, Kilfeather S, Cheung D, et al. Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks. Eur Respir J. 2002;20(Suppl. 38):406s (Abstract 2579). Pearlman DS, Berger WE, Kerwin E, LaForce C, Kundu S, Banerji D. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild- to-moderate persistent asthma. J Allergy Clin Immunol. 2005;116:1206–1212. Pedersen S, Garcia ML, Manjra AI, Vermeulen JH, Venter L, Engelstätter R. Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. Eur Respir J. 2004a;24(Suppl. 48):346s(Abstract 2176). Pedersen S, Gyurkovits K, von Delft KHE, Boss H, Engelstätter R. Safety profile of ciclesonide as compared with fluticasone propionate in the treatment of children and adolescents with asthma. Eur Respir J. 2004b;24(Suppl. 48):346s. (Abstract 2175). Postma DS, Sevette C, Martinat Y, Schlosser N, Aumann J, Kafe H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J. 2001;17:1083–1088. Postma DS, Ind PW, Magnussen H, van den Berge M. A double-blind, randomized, controlled study comparing the efficacy and safety of inhaled ciclesonide with oral prednisolone in patients with an asthma exacerbation. Poster presented at: American Thoracic Society Annual Meeting; May 21, 2006; San Diego, CA. Poster G27. Reynolds NA, Scott LJ. Ciclesonide. Drugs. 2004;64:511–519; discussion 520–521. Richter K, Kanniess F, Biberger C, Nave R, Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol. 2005;45:146–152. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther. 2005;12:201–209. Roland NJ, Bhalla R, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126:213–219. Sanjuas C, Alonso J, Prieto L, et al. Health-related quality of life in asthma: a comparison between the St George's respiratory questionnaire and the asthma quality of life questionnaire. Qual Life Res. 2002;11:729–738. Sin DD, Man J, Sharpe H, Gan WQ, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta- analysis. JAMA. 2004;292:367–376. Skoner D, Maspero J, Kundu S, Loyd M, Banerji D. Ciclesonide, administered once daily, has no effect on growth velocity in prepubertal children with mild, persistent asthma. J Allergy Clin Immunol. 2006;117(Suppl. 2):S11 (Abstract 44). Subbarao P, Duong M, Adelroth E, et al. Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol. 2006;117:1008–1013. Szefler S, Rohatagi S, Williams J, Lloyd M, Kundu S, Banerji D. Ciclesonide, a novel inhaled steroid does not affect hypothalamic–pituitary–adrenal axis function in patients with moderate-to-severe persistent asthma. Chest. 2005;128:1104–1114. Taylor DA, Jensen MW, Kanabar V, et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5'- monophosphate in asthmatic patients. Am J Respir Crit Care Med. 1999;160:237–243. Ukena D, Biberger C, von Behren V, et al. Ciclesonide significantly improves pulmonary function when compared with budesonide: a randomized 12-week study. Eur Respir J. 2003;22(Suppl. 45):411s (Abstract 2640). van der Molen R, Postma D, Schreurs A, et al. Discriminative aspects of two generic and two asthma-specific instruments: relation with symptoms, bronchodilator use and lung function in patients with mild asthma. Qual Life Res.1997;6:353–361. van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid- induced osteoporosis: a meta analysis. Osteoporos Int. 2002;13:777–787. Vermeulen JH, Latos T, Müller T, Engelstätter R. Quality of life is improved by ciclesonide 160 mcg once daily and budesonide 400 mcg once daily in pediatric patients with persistent asthma. J Allergy Clin Immunol. 2006;117(Suppl. 2):S184 (Abstract 716). © 2006 Core Medical Publishing Limited